Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Core Insights - The roundtable discussion hosted by Lexicon Pharmaceuticals focused on enhancing legislative efforts to address chronic pain treatment needs in the U.S. [1][3] - Approximately 50 million Americans suffer from chronic pain, with associated costs reaching up to $635 billion annually [2] - The Alternatives to PAIN Act aims to improve access to non-opioid pain treatments under Medicare Part D, currently limited to acute and post-surgical pain [3][4] Legislative Focus - Participants discussed the need to expand the Alternatives to PAIN Act to include chronic pain sufferers [3] - The group emphasized the importance of innovation in pain treatment, highlighting that pain remains an undertreated condition [4] Company Overview - Lexicon Pharmaceuticals is dedicated to pioneering medicines that transform patients' lives, utilizing its Genome5000™ program for drug discovery [5] - The company has a pipeline of drug candidates targeting various conditions, including neuropathic pain and obesity [5]